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PCLINICAL RESEARCH Acute MI and Antiplatelet Therapy
Role of Clopidogrel Loading Dose
in Patients With ST-Segment Elevation
Myocardial Infarction Undergoing Primary Angioplasty
Results From the HORIZONS-AMI (Harmonizing Outcomes
With Revascularization and Stents in Acute Myocardial Infarction) Trial
George Dangas, MD, PHD,*† Roxana Mehran, MD,*† Giulio Guagliumi, MD,‡
Adriano Caixeta, MD, PHD,*† Bernhard Witzenbichler, MD,§ Jiro Aoki, MD, PHD,*† Jan Z. Peruga, MD,
Bruce R. Brodie, MD,¶ Dariusz Dudek, MD,# Ran Kornowski, MD,** LeRoy E. Rabbani, MD,*
Helen Parise, SCD,*† Gregg W. Stone, MD,*† for the HORIZONS-AMI Trial Investigators
New York, New York; Bergamo, Italy; Berlin, Germany; Lodz and Krakow, Poland;
Greensboro, North Carolina; and Petach Tikva, Israel
Objectives Our aim was to determine whether a 600-mg loading dose of clopidogrel compared with 300 mg results in im-
proved clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing pri-
mary percutaneous coronary intervention (PCI).
Background A 600-mg loading dose of clopidogrel compared with 300 mg provides more rapid and potent inhibition of plate-
let activation.
Methods In the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction)
trial, 3,602 patients with STEMI undergoing primary PCI were randomized to bivalirudin (n  1,800) or unfrac-
tionated heparin plus a glycoprotein IIb/IIIa inhibitor (n  1,802). Randomization was stratified by thienopyri-
dine loading dose, which was determined before random assignment.
Results Patients in the 600-mg (n  2,158) compared with the 300-mg (n  1,153) clopidogrel loading dose group had
significantly lower 30-day unadjusted rates of mortality (1.9% vs. 3.1%, p  0.03), reinfarction (1.3% vs. 2.3%,
p  0.02), and definite or probable stent thrombosis (1.7% vs. 2.8%, p  0.04), without higher bleeding rates.
Compared with unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor, bivalirudin monotherapy resulted in
similar reductions in net adverse cardiac event rates within the 300-mg (15.2% vs. 12.3%) and 600-mg (10.4%
vs. 7.3%) clopidogrel loading dose subgroups (pinteraction  0.41). By multivariable analysis, a 600-mg clopi-
dogrel loading dose was an independent predictor of lower rates of 30-day major adverse cardiac events (hazard
ratio: 0.72 [95% confidence interval: 0.53 to 0.98], p  0.04).
Conclusions In patients with STEMI undergoing primary PCI with contemporary anticoagulation regimens, a 600-mg loading dose
of clopidogrel may safely reduce 30-day ischemic adverse event rates compared with a 300-mg loading dose.
(Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI];
NCT00433966) (J Am Coll Cardiol 2009;54:1438–46) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.021p
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October 6, 2009:1438–46 Clopidogrel Loading Before Primary Angioplastynvestigated the optimal clopidogrel loading dose in patients
ith stable angina and non–ST-segment elevation myocar-
ial infarction undergoing PCI (11–14). In these studies, a
00-mg loading dose of clopidogrel consistently led to greater
latelet inhibition compared with 300 mg (11,13,14). A
00-mg clopidogrel loading dose followed by 75 mg
See page 1447
aily in addition to aspirin has also proven beneficial over
spirin alone in patients with acute myocardial infarction (MI)
reated with fibrinolytic therapy (15,16). Neither loading dose
f clopidogrel has been studied in patients with acute MI
ndergoing primary PCI.
In the multicenter prospective, randomized HORIZONS-
MI (Harmonizing Outcomes With Revascularization and
tents in Acute Myocardial Infarction) trial (17), 3,602
T-segment elevation myocardial infarction (STEMI) pa-
ients undergoing a primary PCI strategy were randomly
ssigned to either unfractionated heparin (UFH) plus glyco-
rotein IIb/IIIa inhibitors (GPIs) or bivalirudin mono-
herapy after stratification according to thienopyridine load-
ng dose. In the present study, we evaluated the impact of
lopidogrel loading with 600 mg versus 300 mg on 30-day
linical outcomes.
ethods
atient population and study protocol. The HORIZONS-
MI trial design has been described elsewhere (17). In
rief, this study was a prospective, open label, 2  2
actorial randomized multicenter trial of 3,602 patients
nrolled at 123 centers worldwide. The study protocol
as approved by the institutional review board or ethics
ommittee at each center, and written informed consent
as obtained from all patients. Patients were randomized
:1 in the emergency room to either administration of
nticoagulation with UFH plus routine use of a GPI or
ivalirudin plus bail-out GPI use reserved for refractory
o-reflow or giant thrombus. After angiography, patients
ith lesions eligible for stenting then underwent a second
andomization (3:1) to either Taxus Express-2 paclitaxel-
luting stents or otherwise identical uncoated Express-2
are-metal stents (both Boston Scientific, Natick, Mas-
achusetts). UFH was administered intravenously as a
0-IU/kg bolus with subsequent boluses to achieve an
ctivated clotting time of 200 to 250 s. Bivalirudin was
dministered intravenously as a 0.75-mg/kg bolus plus
nfusion of 1.75 mg/kg/h. Aspirin (100 to 324 mg orally
r 500 mg intravenously) was administered daily during
he index hospitalization, and 75 to 100 mg/day was
rescribed indefinitely after discharge. GPI treatment
ith either abciximab (0.25 mg/kg bolus plus 0.125
g/kg/min infusion, maximum 10 g/min) or double-
olus eptifibatide (180 g/kg bolus plus 2.0 g/kg/min
nfusion, with a second bolus given in 10 min) was mermitted per investigator dis-
retion, adjusted for renal im-
airment per Food and Drug
dministration label, and con-
inued for 12 h (abciximab) or
2 to 18 h (eptifibatide).
The initial loading dose of
hienopyridine was left to the
nvestigator’s discretion, although
t least a 300-mg clopidogrel
oading dose was required to be
dministered in the emergency
oom per the trial protocol. Clo-
idogrel (75 mg/day) was man-
ated for 6 months (1 year
ecommended) after discharge.
iclopidine was permitted in the
ase of clopidogrel allergy or un-
vailability.
The primary randomization
as stratified by whether the
atient was to be loaded with 300 mg of clopidogrel, 600
g of clopidogrel, or 500 mg of ticlopidine before
atheterization.
linical end points and definitions. The primary end
oint definitions have been previously detailed (17). Compos-
te major adverse cardiovascular events (MACE) (including
eath from any cause, stroke, reinfarction, and unplanned
evascularization for ischemia) and major bleeding were adju-
icated by an independent clinical events committee blinded to
reatment assignment with review of original source docu-
ents. Net adverse clinical events (NACE) were defined as the
ccurrence of MACE or major bleeding unrelated to coronary
rtery bypass grafting (CABG).
tatistical analysis. Continuous variables were expressed as
edian and interquartile range and were compared using
ilcoxon rank sum test. Categorical variables were compared
ith the chi-square test or Fisher exact test. Cox proportional
azards regression was performed to identify the predictors of
0-day MACE and major bleeding unrelated to CABG.
nteractions were tested by including the cross product of the
variables (an interaction term) in the Cox model. The
ultivariable model was built by stepwise variable selection
ith entry and exit criteria set at the p  0.1 level. The
ollowing patient level candidate predictors were evaluated:
ge, women, height, weight, hypertension, hyperlipidemia,
moking, diabetes, family history of pre-mature coronary artery
isease, previous MI, previous PCI, previous CABG, previous
ngina, previous congestive heart failure, history of peripheral
ascular disease, baseline Killip class 1, baseline thrombocyto-
enia, baseline anemia (defined as baseline hematocrit below
9% for men and 36% for women), creatinine clearance,
umber of diseased vessels, baseline Thrombolysis In Myocar-
ial Infarction flow grade, worst diameter stenosis, U.S. site,
se of heparin pre-randomization, planned use of GPI, study
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
CABG  coronary artery
bypass grafting
GPI  glycoprotein IIb/IIIa
inhibitor
MACE  major adverse
cardiovascular events
MI  myocardial infarction
NACE  net adverse
clinical events
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
UFH  unfractionated
heparinedication started in emergency room versus cath lab, medi-
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Clopidogrel Loading Before Primary Angioplasty October 6, 2009:1438–46ation use in the past 5 days at home (aspirin, beta-blocker,
hienopyridines, calcium blocker, angiotensin-converting en-
yme inhibitor, angiotensin receptor blocker, sildenafil ci-
rate, diuretics, digoxin, hormone replacement therapy,
miodarone, or cyclooxygenase-2 inhibitor), randomization
Figure 1 Flow Chart of the Present Study
Enrollment and follow-up of the patients (pts) in the trial. HORIZONS-AMI 
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial
Infarction; STEMI  ST-segment elevation myocardial infarction.
Baseline Characteristics According to ClopidogrTable 1 Baseline Characteristics According
300
Age (yrs), median (IQR) 6
Men
Body mass index (kg/m2), median (IQR) 2
Hypertension
Hyperlipidemia
Current smoking
Diabetes mellitus
Insulin requiring
Anemia*
History of prior myocardial infarction
History of prior PCI
History of prior CABG
History of peripheral vascular disease
History of congestive heart failure
History of renal insufficiency†
Creatinine clearance (ml/min), median (IQR) 8
Platelet count ( 103 cells/mm3), median (IQR) 25
Killip class 2 to 4
LVEF 40%
Symptom onset to hospital emergency unit (h),
median (IQR)
Randomization
UFH plus a GPI
Bivalirudin monotherapy
*Anemia is defined as baseline hematocrit39 for men and36 for w
rate of 60 ml/min as determined by the Cockcroft-Gault equation.CABG  coronary artery bypass graft surgery; GPI  glycoprotein IIb/IIIa
fraction; PCI  percutaneous coronary intervention; UFH  unfractionated herm (bivalirudin vs. heparin plus GPI), and 300- versus
00-mg loading dose of clopidogrel. Clopidogrel loading dose
as forced into the multivariable model as an entry criteria
ince it is the variable of interest for MACE and bleeding. For
ajor bleeding predictors, intra-aortic balloon pump and
losure device use were also added to the multivariate model,
ince in previous studies they have been associated with
leeding post-PCI.
In order to adjust for potential selection biases and
otential confounding, patients in the 300 mg and 600
g clopidogrel groups were matched using propensity
cores (18). A logistic regression model was fit relating
lopidogrel group (600 mg vs. 300 mg) to pre-treatment
atient characteristics. Patients were then matched based
n the resulting propensity score using the Caliper
atching algorithm and the SAS “GREEDY” macro
SAS Institute, Cary, North Carolina). Outcomes were then
odeled in this matched subset. All statistical tests were
-tailed. Statistical significance was set at a level of 0.05.
esults
atient characteristics. Of 3,602 patients enrolled in the
ORIZONS-AMI trial, 291 patients were excluded
rom the present study, including 143 patients treated
ith thienopyridines before the randomization, 13 pa-
ading Doselopidogrel Loading Dose
oading Dose
1,153)
600-mg Loading Dose
(n  2,158) p Value
.9–70.5) 60.1 (52.2–69.3) 0.14
.5% 76.9% 0.39
.6–30.1) 27.0 (24.5–30.3) 0.50
.9% 52.7% 0.63
.5% 42.4% 0.62
.4% 47.4% 0.03
.6% 15.6% 0.13
.7% 4.5% 0.27
.4% 10.7% 0.25
.6% 9.8% 0.89
.5% 9.4% 0.39
.3% 2.9% 0.26
.9% 4.5% 0.46
.3% 2.9% 0.26
.9% 3.1% 0.86
.0–113.9) 90.5 (69.6–114.3) 0.02
0.0–299.0) 245.0 (207.0–287.0) 0.02
.5% 6.9% 0.0001
.1% 13.7% 0.28
3–4.0) 2.2 (1.3–3.8) 0.31
.7% 49.2% 0.44
.3% 50.8% 0.44
†renal insufficiency was defined as a calculated creatinine clearanceel Loto C
-mg L
(n 
0.5 (52
75
7.1 (24
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3
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omen;inhibitor; IQR  interquartile range; LVEF  left ventricular ejection
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October 6, 2009:1438–46 Clopidogrel Loading Before Primary Angioplastyients loaded with ticlopidine, 27 patients who were
reated with a clopidogrel loading dose other than 300 or
00 mg, and 108 patients without thienopyridine loading
ose data (Fig. 1). The present study cohort was thus
omposed of 3,311 patients, including 1,153 patients who
eceived a 300-mg loading dose of clopidogrel and 2,158
atients who received a 600-mg loading dose of clopi-
ogrel before cardiac catheterization. Baseline clinical
haracteristics were generally well matched between the 2
roups except for higher prevalence of current smoking,
illip class 1 on presentation, higher baseline creatinine
learance, and lower platelet count in the 600-mg com-
ared with the 300-mg group (Table 1). Additionally,
atients in the 600-mg group were more likely to be
reated with the femoral approach and with a closure
evice, but less likely to have a central venous access and
ntra-aortic balloon pump use (Table 2).
Procedural Characteristics According to ClopidoTable 2 Procedural Characteristics Accordin
300-
GPI administered
Diagnostic catheterization
Femoral artery access
Radial artery access
Venous access obtained
Primary management strategy
Primary PCI
Deferred PCI
CABG without PCI
Medical management only
PCI cohort
Symptom onset to first balloon inflation (h),
median (IQR)
3
1 or more stents implanted, median (IQR)
Number of stents implanted 1
Total stent length implanted 24
Multiple vessels treated
Multiple lesions treated
Closure device
Intra-aortic balloon pump use
Index PCI vessels
Left anterior descending
Left circumflex
Right coronary artery
Left main coronary artery
Saphenous vein graft
Internal mammary artery
TIMI flow grade pre-PCI*
0/1
2
3
Final TIMI flow grade after PCI*
0/1
2
3*Core laboratory angiographic assessment.
TIMI  Thrombolysis In Myocardial Infarction; other abbreviations as in Tablinical outcomes. By univariate analysis, the 30-day
ates of mortality, reinfarction, MACE, and non–
ABG-related major bleeding were significantly lower in
he 600-mg clopidogrel loading dose group compared
ith the 300-mg loading dose group (Table 3, Fig. 2).
he incidence of acquired thrombocytopenia was similar be-
ween the 2 groups. Among patients treated with PCI and
oronary stent implantation, definite or probable stent throm-
osis was also significantly lower among patient in the 600-mg
ompared with the 300-mg loading dose group (1.7% vs. 2.8%,
 0.04).
ffect of clopidogrel loading dose within each random-
zation arm. As shown in Figure 3, the unadjusted rates of
ACE, major bleeding, and MACE tended to be lower
ith the 600-mg compared with the 300-mg clopidogrel
oading dose in both the heparin plus GPI and bivalirudin
onotherapy arms. In this regard, there was no signifi-
Loading DoseClopidogrel Loading Dose
ading Dose
,153)
600-mg Loading Dose
(n  2,158) p Value
2% 54.1% 0.54
3% 96.7% 0.0001
4% 2.9% 0.0001
1% 8.0% 0.03
2% 94.5% 0.13
2% 0.1% 1.00
8% 1.1% 0.09
8% 4.2% 0.46
,077 n  2,043
–5.8) 3.6 (2.6–5.5) 0.0003
6% 96.3% 0.31
–2.0) 1.0 (1.0–2.0) 0.06
.0–36.0) 24.0 (18.0–36.0) 0.008
5% 4.1% 0.68
9% 11.3% 0.26
3% 33.2% 0.0001
5% 4.8% 0.04
9% 40.3% 0.38
5% 15.8% 0.80
6% 42.6% 0.28
7% 0.5% 0.41
2% 0.8% 0.25
1% 0.0% 0.35
4% 59.3% 0.09
2% 13.5% 0.57
3% 27.1% 0.02
6% 2.8% 0.70
3% 9.7% 0.02
1% 87.5% 0.06grelg to
mg Lo
(n  1
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Clopidogrel Loading Before Primary Angioplasty October 6, 2009:1438–46ant interaction between the randomization arm and
lopidogrel loading dose group (p values for interaction
0.48 for NACE, 0.41 for major bleeding, and 0.75 for
ACE). Outcomes of the primary randomization to
ivalirudin versus heparin plus GPI within the subsets of
atients receiving either 600 mg or 300 mg clopidogrel
oading dose are shown in Figure 4.
ultivariable analysis. Independent predictors of MACE
nd major bleeding unrelated to CABG at 30 days by
ultivariable analysis are listed in Table 4. A 600-mg rather
han a 300-mg loading dose of clopidogrel was an indepen-
ent predictor of 30-day MACE (hazard ratio: 0.72 [95%
onfidence interval: 0.28 to 0.6]; p 0.04), but not of major
leeding.
ropensity score-matched patients. A total of 2,254
atched cases, 1,127 in each of the clopidogrel 300- and
00-mg groups were found. Results were similar to the
ain analysis in the full cohort; Table 5 summarizes the
ndependent predictors of MACE and major bleeding at 30
0-Day Clinical Outcomesccording to Clopidogrel Loading DoseTable 3 30-Day Clinical OutcomesAccording to Clopidogrel Loading Dose
300-mg
Loading Dose
(n  1,153)
600-mg
Loading Dose
(n  2,158) p Value
NACE 14.3% 9.0% 0.0001
MACE 7.0% 4.3% 0.001
Death 3.1% 2.0% 0.03
Cardiac 2.7% 1.9% 0.11
Noncardiac 0.4% 0.1% 0.04
Reinfarction 2.6% 1.4% 0.01
Q-wave 1.6% 1.1% 0.27
Non–Q-wave 1.0% 0.3% 0.02
Death or reinfarction 5.4% 3.1% 0.001
Stroke 1.0% 0.5% 0.13
Ischemic target vessel revascularization 2.7% 1.9% 0.11
Stent thrombosis, ARC definite or
probable
3.1% 2.0% 0.05
Bleeding
Major bleeding (non–CABG-related) 9.4% 6.1% 0.0005
Major bleeding (including CABG) 11.4% 7.5% 0.0002
Minor bleeding 13.8% 11.3% 0.03
TIMI bleeding, any 10.2% 6.4% 0.0001
Minor 5.7% 2.2% 0.0001
Major 4.6% 3.6% 0.14
GUSTO bleeding, any 11.6% 7.6% 0.0001
Severe/life-threatening 0.6% 0.4% 0.45
Moderate 5.1% 3.3% 0.01
Mild 6.2% 3.9% 0.003
Severe/life-threatening/moderate 5.4% 3.6% 0.02
Thrombocytopenia (103 cells/mm3)
Platelet count 10,0000 3.5% 2.9% 0.34
Platelet count 50,000 0.8% 0.9% 0.66
Platelet count 20,000 0.3% 0.3% 1.00
RC  Academic Research Consortium; CABG  coronary artery bypass graft surgery; GUSTO 
lobal Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary
rteries; MACEmajor adverse cardiac events: death, reinfarction, target vessel revascularization,
r stroke; NACE  net adverse clinical events: major adverse cardiac events or major bleeding
non–coronary artery bypass graft surgery-related); TIMI  Thrombolysis In Myocardial Infarction.ays among propensity score-matched patients. A 600-mgather than a 300-mg loading dose of clopidogrel remained
n independent predictor of 30-day MACE after propensity
core matching (hazard ratio: 0.67 [95% confidence interval:
.47 to 0.96]; p  0.03).
iscussion
he present study represents the first large report examining
he impact of a 600-mg versus a 300-mg loading dose of
lopidogrel on the clinical outcomes of patients with
TEMI undergoing primary PCI. The major findings of
he present study are that in patients with STEMI under-
oing primary PCI: 1) a 600-mg compared with a 300-mg
oading dose of clopidogrel was associated with lower
0-day rates of mortality, reinfarction, and stent thrombo-
is, and was, by multivariable analysis, an independent
redictor of freedom from 30-day MACE; 2) the 600-mg
oading dose was not associated with increased rates of
ajor bleeding or thrombocytopenia; and 3) compared with
eparin plus a GPI, the clinical benefits of bivalirudin
onotherapy in reducing major bleeding and NACE were
ndependent of the loading dose of clopidogrel, although
verall adverse event rates were lower after a 600-mg
oading dose than a 300-mg loading dose with both anti-
oagulation regimens.
Clopidogrel is well established for use in patients with
CS at a loading dose of 300 mg followed by a maintenance
osage of 75 mg/day. At this loading dose, inhibition of
latelet aggregation is approximately 30% to 40%, and the
ime to peak effect is approximately 4 to 6 h. Several studies
ave shown greater inhibition with faster onset of action
ith a 600-mg compared with a 300-mg clopidogrel load-
ng dose, which may be important in patients with STEMI
n whom the duration from thienopyridine administration
o PCI is abbreviated (3,9). Increasing the dosage from 300
o 600 mg increases the platelet aggregation inhibition to
ver 40% and significantly reduces the incidence of clopi-
ogrel hyporesponsiveness. Delays in drug absorption
Figure 2 30-Day Clinical Outcomes
Subgroup analysis for the 30-day rates of death, reinfarction,
and major bleeding according to clopidogrel loading dose. p  0.0005.
a
a
c
a
s
s
(
D
4
c
p
b
p
r
(
s
c
s
t
l
w
t
s
s
1443JACC Vol. 54, No. 15, 2009 Dangas et al.
October 6, 2009:1438–46 Clopidogrel Loading Before Primary Angioplastynd/or metabolism in the acute MI setting may further
ffect drug pharmacokinetics and pharmacodynamics. The
linical utility of the 600-mg clopidogrel loading dose in
cute MI has been controversial, despite a meta-analysis of
tudies in PCI patients without acute MI that demonstrated
ignificant benefits of this dose (19). The ARMYDA-2
Antiplatelet Therapy for Reduction of Myocardial Damage
uring Angioplasty) study reported that when administered
to 8 h before PCI in the nonurgent setting, a 600-mg
lopidogrel loading dose was more effective than 300 mg in
reventing periprocedural myonecrosis (14), although a
enefit of the higher loading dose was not demonstrated in
Figure 3 Clinical Outcomes at 30 Days According to Stratificat
Clinical outcomes according to clopidogrel loading dose stratified treatment within
unfractionated heparin plus glycoprotein IIb/IIIa inhibitor arms. MACE  major adv
Figure 4 Clinical Outcomes at 30 Days According to Randomiz
Clinical outcomes according to randomization to bivalirudin (Biv) monotherapy vers
glycoprotein IIb/IIIa inhibitor (GPI) within the groups of 600- and 300-mg clopidogreatients with stable angina undergoing PCI from a recently
eported randomized trial or a large single-center experience
20,21). In patients with non–STEMI undergoing PCI,
uperior efficacy of a 600-mg compared with 300-mg
lopidogrel loading dose has been demonstrated in 2 small
tudies (11,12). The present study extends the findings from
hese reports in demonstrating the utility of a 600-mg
oading dose of clopidogrel in patients with STEMI in
hom the time from clopidogrel administration to PCI is
ypically 90 min. By both multivariable and propensity
core adjustment, the higher clopidogrel loading dose was a
ignificant predictor of freedom from MACE at 30 days,
valirudin monotherapy and the
ardiac events; NACE  net adverse clinical events.
signments
ractionated heparin (UFH) plus
ing doses. Abbreviations as in Figure 3.ion
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hrombosis rates.
Of note, in the present study, the 600-mg compared with
he 300-mg loading dose of clopidogrel was not associated
ith greater rates of major bleeding, even after multivariable
nalysis. Indeed, a trend toward a lower adjusted rate of
leeding complications was evident with the higher 600-mg
oading dose. A similar trend was reported from an analysis
f the combined GUSTO (Global Utilization of Streptoki-
ase and Tissue Plasminogen Activator for Occluded Cor-
nary Arteries) I and III studies, which demonstrated that
igher initial aspirin doses (163 to 330 mg) were associated
ith less in-hospital bleeding compared with lower aspirin
oses in patients with STEMI treated with fibrinolytic
herapy (22). The higher use of intra-aortic balloon pump
nd venous access could explain the higher bleeding rates in
he 300-mg group in the present study (Table 2); by
ultivariate analysis, intra-aortic balloon pump was a pre-
ictor of bleeding whereas the clopidogrel dose was not.
In the present study, the clinical advantages of the
00-mg compared with the 300-mg clopidogrel loading
ose were observed in patients treated with UFH plus GPI
s well as with bivalirudin monotherapy. Prior studies have
escribed that the administration of larger (300 mg) oral
oading doses of clopidogrel may accelerate the time course
nd enhance the magnitude of subsequent platelet inhibi-
ion as well as reduce platelet reactivity in patients receiving
PI (23,24). In patients receiving UFH without GPI,
ignificantly greater inhibition of adenosine diphosphate-
nduced platelet activation has been reported with a 600-mg
ompared with a 300-mg clopidogrel loading dose within 2
ndependent Predictors of 30-Daylinical Events in the Full CohortTable 4 Independ nt Predictors of 30-DayClinical Events in the Full Cohort
Hazard
Ratio 95% CI p Value
MACE
Killip class 1 0.41 0.28–0.6 0.001
Clopidogrel 600-mg loading dose 0.72 0.53–0.98 0.04
Platelet count (103 cells/mm3) 1.002 1.00–1.004 0.03
Age 1.03 1.02–1.05 0.001
U.S. site 1.49 1.07–2.08 0.02
History of CHF 1.76 0.94–3.27 0.076
History of peripheral vascular disease 1.87 1.12–3.12 0.02
Major bleeding
Randomization to bivalirudin 0.57 0.43–0.75 0.001
Killip class 1 0.63 0.44–0.91 0.01
Creatinine clearance (ml/min) 0.99 0.98–0.99 0.002
Female sex 1.45 1.08–1.93 0.01
Anemia at baseline 1.62 1.13–2.32 0.008
U.S. site 2.44 1.84–3.23 0.001
Intra-aortic balloon pump use 3.53 2.49–5.01 0.001
Closure device 0.80 0.57–1.11 0.17
Clopidogrel 600-mg loading dose 0.87 0.66–1.14 0.30
HF  congestive heart failure; CI  confidence interval; MACE  major adverse cardiac events:
eath, reinfarction, target vessel revascularization, or stroke.o 3 h after administration (23,25), an effect that persists for
68 h (26). Whether the same applies for bivalirudin-treated
atients has not been studied. Moreover, the relevance of
hese studies in patients with ACS and STEMI is uncer-
ain, because these patients have increased baseline indexes
f platelet activation compared with patients without ACS
10), and primary PCI is often completed well under 2 h
rom clopidogrel administration. The present study suggests
hat the benefits of clopidogrel in patients undergoing an
arly invasive strategy may be enhanced by increasing the
oading dose to 600 mg. This hypothesis is being further
ested in the CURRENT-OASIS 7 (Clopidogrel Optimal
oading Dose Usage to Reduce Recurrent EveNTs-
ptimal Antiplatelet Strategy for InterventionS) trial in
hich patients with ACS are randomized to a 600-mg dose
egimen of clopidogrel versus the standard dose regimen of
00-mg loading dose followed by 75 mg daily.
Importantly, the previously reported beneficial effects of
ivalirudin compared with UFH plus GPI in reducing
ACE and major bleeding while affording similar rates of
ACE in patients with STEMI undergoing primary PCI
17) were independent of clopidogrel loading dose, although
he overall adverse event rates were lower after a 600-mg
oading dose with both anticoagulation regimens. Of note,
ven after a 600-mg clopidogrel loading dose, the full
ntiplatelet effect of the drug is achieved only after 2 h, and
ith wide individual variability (27). This observation sug-
ests that a faster acting and more potent agent might
urther enhance the clinical benefit of early platelet inhibi-
ion before primary PCI in STEMI. Prasugrel, a novel
hienopyridine antiplatelet agent, has a more rapid onset of
ction and is more potent than clopidogrel (80% inhibi-
ndependent Predictors of 30-Day Clinicalvents Among Propen ity-Matched Patients*Table 5 Ind penden Predictors of 30-Day ClinicalEvents Among Propensity-Matched Patients*
Hazard
Ratio 95% CI p Value
MACE
Killip class 1 0.36 0.24–0.55 0.001
Clopidogrel 600-mg loading dose 0.67 0.47–0.96 0.03
Platelet count (103 cells/mm3) 1.002 1.00–1.004 0.021
Age 1.04 1.02–1.05 0.001
U.S. site 1.46 1.01–2.12 0.045
History of CHF 1.60 0.70–3.67 0.27
History of peripheral vascular disease 2.04 1.14–3.64 0.016
Major bleeding
Randomization to bivalirudin 0.58 0.43–0.78 0.0004
Killip class 1 0.58 0.39–0.86 0.0072
Creatinine clearance (ml/min) 0.99 0.98–0.99 0.0001
Women 1.53 1.10–2.11 0.01
Anemia at baseline 1.82 1.21–2.74 0.0043
U.S. site 2.37 1.73–3.25 0.001
Intra-aortic balloon pump use 3.50 2.37–5.16 0.001
Closure device 0.85 0.58–1.24 0.39
Clopidogrel 600-mg loading dose 0.90 0.66–1.20 0.47
A total of 2,254 matched cases, 1,127 patients each treated with clopidogrel 300 mg and
00 mg.
Abbreviations as in Table 4.
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October 6, 2009:1438–46 Clopidogrel Loading Before Primary Angioplastyion of platelet aggregation) (28). In the TRITON–TIMI
8 (Trial to Assess Improvement in Therapeutic Outcomes
y Optimizing Platelet Inhibition with Prasugrel–
hrombolysis In Myocardial Infarction 38) trial, random-
zation of 3,354 patients with acute or recent STEMI
ndergoing PCI to a 60-mg prasugrel load rather than a
00-mg clopidogrel load each followed by a daily mainte-
ance dosage over 15 months resulted in a significant
eduction in the composite end point of cardiovascular
eath, MI, or stroke at 30 days and 15 months as well as
igher rate of bleeding in patients who underwent CABG
urgery (29). However, among the 2,438 patients enrolled
ith STEMI within 12 h undergoing primary PCI, the
0-day hazard reduction with prasugrel was less than in the
,094 randomized patients with a recent STEMI within 14
ays (0.92 vs. 0.50, respectively), possibly due to the fact
hat most patients received both thienopyridine agents for
he first time at or after the time of the PCI procedure (29).
comparison between a 600-mg clopidogrel loading dose
nd a prasugrel 60-mg loading dose initiated as early as
ossible (e.g., in the ambulance or emergency room) in
atients with STEMI undergoing primary PCI has not
een performed. The results of the present study do suggest,
owever, that the dosing and timing of thienopyridine
gents before primary PCI may importantly impact clinical
utcomes, thus warranting the further evaluation of the
fficacy and safety of more potent antiplatelet agents in
TEMI.
Several caveats of the present report should be acknowl-
dged. As an observational (though pre-specified) analysis of
he HORIZONS-AMI trial, the results should be confirmed
n dedicated randomized studies. Although the clopidogrel
oading dose was stratified before the randomization (ensuring
alance of this variable according to anticoagulation regimen),
he 300-mg versus 600-mg loading dose itself was not ran-
omized, resulted in imbalance in several baseline, angio-
raphic, and procedural characteristics. Despite the use of
ultivariable and propensity score analysis to correct for these
ifferences in measured confounders, it is unknown whether
nmeasured confounders are present that may have affected the
esults. A previous study has suggested that matching accord-
ng to the propensity score eliminates a greater proportion of
aseline differences between 2 treatments than does stratifica-
ion or covariate adjustment (30). Nevertheless, the propensity
core matching technique cannot entirely adjust for unmea-
ured patient characteristics that might influence assignment to
he clopidogrel treatment group. Finally, the impact of clopi-
ogrel resistance and potential drug-drug interactions such as
etween clopidogrel and proton pump inhibitors were not
valuated in the present study (31,32).
onclusions
n the large-scale, multicenter HORIZONS-AMI trial, a
00-mg loading dose of clopidogrel was associated with
ower rates of 30-day mortality, reinfarction, subacute stent
1hrombosis, and composite MACE compared with a 300
g loading dose, without increase rates of bleeding in
atients with STEMI undergoing primary PCI. Compared
ith UFH plus a GPI, the clinical benefits of bivalirudin
onotherapy (less bleeding and NACE, similar MACE)
ere independent of the loading dose of clopidogrel, al-
hough the overall adverse event rates were lower after a
00-mg loading dose of clopidogrel compared with a
00-mg dose with both anticoagulation regimens. Pending
urther studies, these data suggest that the use of 600 mg of
lopidogrel as the loading dose of choice in patients with
TEMI undergoing primary PCI is safe and more effica-
ious than 300 mg.
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